Corneal Allograft Rejection: Risk Factors, Diagnosis, Prevention, and Treatment

Indian Journal of Ophthalmology

Volumn 47, Issue 1, 1999, Pages 3-9

  Dua, Harminder S ^a   Azuara Blanco, Augusto ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Allograft rejection; Keratoplasty; Prevention; Risk factors; Treatment

Indexed keywords

ARTICLE; CORNEA TRANSPLANTATION; GRAFT REJECTION; HUMAN; RISK FACTOR;

CORNEAL TRANSPLANTATION; GRAFT REJECTION; HUMANS; RISK FACTORS;

EID: 0347718217     PISSN: 03014738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Vail A, Gore SM, Bradley BA, Eastly DL, Rogers CA, Armitage WL. Influence of donor and histocompatibility factors on corneal graft outcome. Transplantation 1994;58:1210-17.
2. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival. Ophthalmology 1992;99:403-14.
3. Hill JC. Immunosuppression in corneal transplantation. Eye 1995;9:247-53.
4. The Collaborative Corneal Transplantation Studies (CCTS) Research Group. Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992;110:1392-93.
5. The Collaborative Corneal Transplantation Studies Research Group. Designs and methods of the collaborative corneal transplantation studies. Cornea 1993;12:93-103.
6. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, et al. Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies. Ophthalmology 1994;101:1536-47.
7. Volker-Dieben HJ, D' Amaro J, Kok-Van Alphen CC. Heirarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol 1987;15:11-18.
8. Boisjoly HM, Bernanrd P-M, Dube I, Laughera P-A, Bazin R, Bermier J. Effect of factors unrelated to tissue matching on corneal transplant endothelial rejection. Am J Ophthalmol 1989;107:647-54.
9. Des Marchais B, Bazin R, Boisjoyly HM, Laughera P-A, Dube I, Lille S, et al. Role of presensitization and donor-recipient crossmatching in corneal graft outcome. Cornea 1998;17:141-45.
10. Musch DC, Meyer RF. Risk of endothelial rejection after bilateral penetrating keratoplasty. Ophthalmology 1989;96:1139-43.
11. Sanfilippo F, MacQueen JM, Vaughn WK, Foulks GN. Reduced graft rejection with good HLA-A and B matching in high-risk corneal transplantation. N Engl J Med 1986;315:29-35.
12. Holland EJ, De Ruyter DE, Doughman DJ. Langerhans' cells in organ cultured corneas. Arch Ophthalmol 1987;105:542-45.
13. Vail A, Gore SM, Bradley BA, Eastly DL, Rogers CA, Armitage WL. Clinical and surgiacl factors influencing corneal graft survival, visual acuity, and astigmatism. Ophthalmology 1996;103:41-49.
14. Moll AC, Van Rij G, Beekhuis G, Reneradel De Lavalette JHC, Hermans J, Pels E, et al. Effect of donor cornea preservation in tissue culture and in Mc Carey-Kaufmann medium on corneal graft rejection and visual acuity. Doc Ophthalmol 1991;78:273-78.
15. Kirk PE. Organ transplantation and pregnancy: a case report and review. Am J Obstet Gynecol 1991;164:1629-34.
16. Fulton JC, Cohen EJ, Honig M, Rapuano CJ, Laibson PR. Pregnancy and corneal allograft rejection. Arch Ophthalmol 1996;114:765.
17. McDonnell PJ, Robin JB. Corneal allograft rejection in a pregnant woman. Cornea 1987;6:281-82.
18. Solomon A, Frucht-Pery J. Bilateral simultaneous corneal graft rejection after influenza vaccination. Am J Ophthalmol 1996;121:708-9.
19. Redmond RM, Armitage WJ, Whittle J, Moss SJ, Easty DL. Long-term survival of endothelium following transplantation of corneas stored bv organ culture. Br J Ophthalmol 1992;76:479-81.
20. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection: their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981;99:599-604.
21. Niederkorn JY. Immune privilege and immune regulation in the eye. Adv Immunol 1990;48:191-226.
22. Streilein JW. Immune regulation and the eye: a dangerous compromise. FASEB J 1987;1987;1:199-208.
23. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989;107:506-10.
24. Hill JC. Systemic cyclosporine in high-risk keratoplasty: short versus long term therapy. Ophthalmology 1994;101;128-33.
25. Miller K, Huber C, Niederwieser D, Gottinger W. Successful engraftment of high risk corneal allografts with short term immunosuppression with cyclosporine. Transplantation 1988;45:651-53.
26. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A: background, immunology, and pharmacology. Cornea 1990;9:184-95.
27. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989;96:1144-50.
28. Gregory CR, Hietala SK, Pedersen NC, Gregory TA, Floyd-Hawkins KA, Patz JD. Cyclosporine pharmacokinetics in cats following topical ocular administration. Transplantation 1989;47:516-19.
29. Mayer DJ, Daar AS, Casey TA, Fabre JW. Localisation of HLA-A, B, C, and HLA-DR antigens in the human cornea: practical significance for grafting technique and HLA typing. Transplantation Proceedings 1983;15:126-29.
30. Treseler PA, Foulks GN, Sanfilippo F. The expression of HLA antigens by cells in the human cornea. Am J Opthahlmol 1984;98:763-72.
31. Whitsett CF, Stulting RD. The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Vis Sci 1984;25:519-24.
32. Dua HS, Shidham VB. Application of specific red blood cell adherence test to the human cornea and conjunctiva. Am J Ophthalmol 1979;88:1067-71.
33. Salisbury JD, Gebhardt BM. Blood group antigens on human corneal cells demonstrated by immunoperoxidase staining. Am J Ophthalmol 1981;91:46-50.
34. Boisjoly HM, Roy R, Dube I, et al. HLA-A, B and DR matching in corneal transplantation. Ophthalmology 1986;93:1290-97.
35. Boisjoly HM, Roy R, Bernard P-M, et al. Association between corneal allograft reactions and HLA compatibility. Ophthalmology 1990;97:1689-98.
36. Volker-Dieben HJ, Kok-Van Alphen CC, Lansbergen Q, Persjin GG. Different influences on corneal graft survival in 539 transplants. Acta Ophthalmol 1982;60:190-202.
37. Allansmith MR, Drell DW, Kajiyama G. ABO blood groups and corneal transplantation. Am J Ophthalmol 1975;79:493-501.
38. Ehlers N, Ahrons S. Corneal transplantation and histocompatibility. Acta Ophthalmol 1971;49:513-27.
39. Stark WJ, Taylor HR, Bias WB, Maumenee AE. Histocompatibility (HLA) antigens and keratoplasty. Am J Ophthalmol 1978;86:595-604.
40. Batchelor JR, Casey TA, Werb A, Gibbs DC, Prasad SS, Lloyd DF, et al. HLA matching and corneal grafting. Lancet 1976;i:551-54.
41. Munkhbat B, Hagihara M, Sato T, Tsuchida F, Sato K, Shimazaki J, et al. Association between HLA-DPB1 matching and 1-year rejection-free graft survival in high-risk corneal transplantation. Transplantation 1997;63:1011-16.
42. Dua HS, Chan J, Gomes JAP, Azuara-Blanco A. Adverse effect of blood group ABO mismatching on corneal epithelial cells. Lancet 1998;352:1677-78.
43. Reed JW, Fromer C, Klintworth GK. Induced corneal vascularisation remission with argon laser therapy. Arch Ophthalmol 1975;93:1017-19.
44. Krasnick NM, Spigelman AV. Comparison of yellow dye, continuous wave Nd:YAG, and argon green laser on experimentally induced corneal neovascularization. J Ref Surg 1995;11:45-49.
45. Nirankari VS, Baer JC. Corneal argon laser photocoagulation for neovascularisation in penetrating keratoplasty. Ophthalmology 1986;93:1304-309.
46. Baer CJ, Foster SC. Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser. Ophthalmology 1992;99:173-79.
47. Hill JC, Maske R, Watson PG. The use of a single pulse of intravenous methylprednisolone in the treatment of corneal graft rejection. A preliminary report. Eye 1991;5:420-24.
48. Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology 1991;98:329-33.
49. Barraquer J. Immunosuppressive agents in penetrating keratoplasty. Am J Ophthalmol 1985;100:61-64.
50. Sloper CM, Dua HS, Powell RJ. Tacrolimus in high-risk corneal and limbal grafts. Invest Ophthalmol Vis Sci 1998;39:80.
51. Ma D, Mellon H, Niederkorn JY. Oral immunization as a strategy for enhancing corneal allograft survival. Br J Ophthalmol 1997;81:778-84.
52. Ma D, Mellon J, Niederkorn JY, Conditions affecting enhanced corneal allograft survival by oral immunization. Invest Ophthalmol Vis Sci 1998;39:1835-46.
53. Ma D, Li X-Y, Mellon J, Niederkorn JY. Immunologic phenotype of hosts orally immunized with corneal alloantigens. Invest Ophthalmol Vis Sci 1998;39:744-53.
54. He Y-G, Mellon J, Niederkorn JY. The effect of oral immunization on corneal allograft survival. Transplantation 1996;61:920-26.
55. He Y-G, Niederkorn JY. Depletion of donor-derived Langerhans cells promotes corneal allograft survival. Cornea 1996;15:82-89.
56. Yamagami S, Tsuru T, Isobe M, Osata H, Suzuki J-I. The role of cell adhesion molecules in allograft rejection after penetrating keratoplasty in mice. Clinical and immunohistochemical study. Graefe's Arch Clin Exp Ophthalmol 1996;234:382-87.
57. Pleyer U, Milani JK, Ruckert D, Rieck P, Mondino BJ. Determination of serum tumor necrosis factor alpha in corneal allografts. Ocular Immuno Inflammation 1997;5:149-55.